Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Common racehorse drug could raise risk of sudden death
The scientists identified a significant risk factor associated with horses being given furosemide on race day.
Researchers conduct the first-ever large-scale study of Thoroughbred racing fatalities.

Researchers have discovered that a common drug used in Thoroughbred racehorses could increase the risk of sudden death.

The first-of-its-kind study analysing data from more than four million starts in horse racing across the USA and Canada found that around one in 10,000 resulted in a race-day sudden death.

Scientists identified a significant risk factor associated with the horses being given furosemide on race day. Horses given the drug were 62 per cent more likely to die suddenly, when compared with horses not given furosemide. 

Furosemide is widely used in the US on race days to prevent pulmonary bleeding and is associated with enhanced racing performance. Consequently, 94 per cent of horse starts in the study had been administered with the drug.
 
Scientists discovered that it could also be possible to identify horses at risk of sudden death before they experience it – for example, due to previous injury and interruption to training. Other risk factors highlighted by the study were horse age and sex, season, purse of race and race distance.

Study author Dr Euan Bennet, from the University of Glasgow's School of Biodiversity, One Health and Veterinary Medicine, commented: “This study suggests that a risk profile, identifying which horses are at the greatest risk of sudden death, may be possible. Given how rare the outcome is, further work is required to establish any potential interventions which might contribute to a reduction in sudden deaths. 

“On the association between furosemide use and sudden death, the fact that furosemide use is so common makes this result particularly remarkable given the statistical power of this large-scale study. Discussions around the ethics of race day administration of drugs should factor in potential risks such as those identified here, and further work is required to understand exactly why we identified this association.”

The study, ‘Fifteen risk factors associated with sudden death in Thoroughbred racehorses in North America (2009-2021),’ is published in the
Journal of the American Veterinary Medicine Association. 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.